• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于数据非依赖采集的 FFPE 直肠癌样本质谱分析可深入鉴定新辅助放化疗的反应特征。

Data-Independent Acquisition Mass Spectrometry Analysis of FFPE Rectal Cancer Samples Offers In-Depth Proteomics Characterization of the Response to Neoadjuvant Chemoradiotherapy.

机构信息

Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia.

Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Fleming 34, 166 72 Vari, Greece.

出版信息

Int J Mol Sci. 2023 Oct 21;24(20):15412. doi: 10.3390/ijms242015412.

DOI:10.3390/ijms242015412
PMID:37895091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10607861/
Abstract

Locally advanced rectal cancer (LARC) presents a challenge in identifying molecular markers linked to the response to neoadjuvant chemoradiotherapy (nCRT). This study aimed to utilize a sensitive proteomic method, data-independent mass spectrometry (DIA-MS), to extensively analyze the LARC proteome, seeking individuals with favorable initial responses suitable for a watch-and-wait approach. This research addresses the unmet need to understand the response to treatment, potentially guiding personalized strategies for LARC patients. Post-treatment assessment included MRI scans and proctoscopy. This research involved 97 LARC patients treated with intense chemoradiotherapy, comprising radiation and chemotherapy. Out of 97 LARC included in this study, we selected 20 samples with the most different responses to nCRT for proteome profiling (responders vs. non-responders). This proteomic approach shows extensive proteome coverage in LARC samples. The analysis identified a significant number of proteins compared to a prior study. A total of 915 proteins exhibited differential expression between the two groups, with certain signaling pathways associated with response mechanisms, while top candidates had good predictive potential. Proteins encoded by genes , , , , , and showed high predictive potential of unfavorable treatment outcome, while , , , , , , , , , and were good predictive biomarkers of favorable treatment outcome. The identified proteins and related biological processes provide promising insights that could enhance the management and care of LARC patients.

摘要

局部进展期直肠癌(LARC)在识别与新辅助放化疗(nCRT)反应相关的分子标志物方面存在挑战。本研究旨在利用灵敏的蛋白质组学方法——数据非依赖采集质谱(DIA-MS),对 LARC 蛋白质组进行广泛分析,寻找适合观望等待策略的初始反应良好的个体。这项研究旨在满足了解治疗反应的需求,为 LARC 患者提供潜在的个性化治疗策略。治疗后评估包括 MRI 扫描和直肠镜检查。本研究纳入了 97 例接受强化放化疗的 LARC 患者,包括放疗和化疗。在本研究中,我们从 97 例 LARC 患者中选择了 20 例对 nCRT 反应最不同的样本进行蛋白质组谱分析(应答者与无应答者)。这种蛋白质组学方法在 LARC 样本中显示出广泛的蛋白质组覆盖。与之前的研究相比,该分析确定了大量的蛋白质。两组之间共有 915 种蛋白质表达差异,某些信号通路与反应机制相关,而候选蛋白具有良好的预测潜力。基因 、 、 、 、 、 和 编码的蛋白质显示出不良治疗结果的高预测潜力,而 、 、 、 、 、 、 、 和 是治疗结果良好的良好预测生物标志物。鉴定的蛋白质和相关生物过程提供了有希望的见解,可增强 LARC 患者的管理和护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/2fa41432210f/ijms-24-15412-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/33149c8d053f/ijms-24-15412-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/007abbb619a8/ijms-24-15412-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/2802ccbfb28a/ijms-24-15412-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/a24a79042dda/ijms-24-15412-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/920a193beacd/ijms-24-15412-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/bd23dc83ae2a/ijms-24-15412-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/2fa41432210f/ijms-24-15412-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/33149c8d053f/ijms-24-15412-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/007abbb619a8/ijms-24-15412-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/2802ccbfb28a/ijms-24-15412-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/a24a79042dda/ijms-24-15412-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/920a193beacd/ijms-24-15412-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/bd23dc83ae2a/ijms-24-15412-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57b2/10607861/2fa41432210f/ijms-24-15412-g007.jpg

相似文献

1
Data-Independent Acquisition Mass Spectrometry Analysis of FFPE Rectal Cancer Samples Offers In-Depth Proteomics Characterization of the Response to Neoadjuvant Chemoradiotherapy.基于数据非依赖采集的 FFPE 直肠癌样本质谱分析可深入鉴定新辅助放化疗的反应特征。
Int J Mol Sci. 2023 Oct 21;24(20):15412. doi: 10.3390/ijms242015412.
2
Characterization and proteomic analysis of plasma-derived small extracellular vesicles in locally advanced rectal cancer patients.局部进展期直肠癌患者血浆来源的小细胞外囊泡的表征和蛋白质组学分析。
Cell Oncol (Dordr). 2024 Oct;47(5):1995-2009. doi: 10.1007/s13402-024-00983-1. Epub 2024 Aug 20.
3
Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response.局部进展期直肠癌转录组学分泌组分析揭示了新的生物标志物,可用于根据新辅助放化疗反应来识别患者。
Sci Rep. 2019 Jun 18;9(1):8702. doi: 10.1038/s41598-019-45151-w.
4
FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients.FOSL2 促进局部晚期直肠癌患者肿瘤内 T 细胞浸润,并提高病理完全缓解率。
Cancer Lett. 2023 May 28;562:216145. doi: 10.1016/j.canlet.2023.216145. Epub 2023 Mar 28.
5
Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.基于小 RNA 测序的肿瘤 microRNAs 可作为局部晚期直肠癌患者接受新辅助放化疗的潜在疗效预测指标。
Cancer Genomics Proteomics. 2020 May-Jun;17(3):249-257. doi: 10.21873/cgp.20185.
6
Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer.使用局部晚期直肠癌的非靶向代谢组学预测新辅助放化疗的病理反应。
Radiother Oncol. 2018 Sep;128(3):548-556. doi: 10.1016/j.radonc.2018.06.022. Epub 2018 Jul 2.
7
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).新辅助 FOLFOXIRI 方案在放化疗前治疗高危(“难看”)局部进展期直肠癌:一项单臂、多中心、开放标签、Ⅱ期试验(MEND-IT)的研究方案。
BMC Cancer. 2022 Sep 6;22(1):957. doi: 10.1186/s12885-022-09947-w.
8
Novel biomarkers to predict treatment response and prognosis in locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy.用于预测接受新辅助放化疗的局部晚期直肠癌的治疗反应和预后的新型生物标志物。
BMC Cancer. 2023 Nov 12;23(1):1099. doi: 10.1186/s12885-023-11354-8.
9
An integrated multiomics analysis of rectal cancer patients identified POU2F3 as a putative druggable target and entinostat as a cytotoxic enhancer of 5-fluorouracil.一项针对直肠癌患者的综合多组学分析确定POU2F3为一个潜在的可成药靶点,而恩替诺特为5-氟尿嘧啶的细胞毒性增强剂。
Int J Cancer. 2023 Jul 15;153(2):437-449. doi: 10.1002/ijc.34478. Epub 2023 Mar 23.
10
Identification of proteomic markers for prediction of the response to 5-Fluorouracil based neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.鉴定蛋白质组学标志物以预测局部晚期直肠癌患者对基于5-氟尿嘧啶的新辅助放化疗的反应。
Cancer Cell Int. 2022 Mar 15;22(1):117. doi: 10.1186/s12935-022-02530-0.

引用本文的文献

1
Proteomic Analysis of FFPE Tissue Samples Identifies Potential Molecular Mechanisms Mediating Resistance to Radiotherapy in Rectal Cancer.福尔马林固定石蜡包埋(FFPE)组织样本的蛋白质组学分析确定了介导直肠癌放疗抗性的潜在分子机制。
J Proteome Res. 2025 Aug 1;24(8):3990-4001. doi: 10.1021/acs.jproteome.5c00114. Epub 2025 Jun 26.
2
Dose Escalation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Short-Term Efficacy and Toxicity of VMAT-SIB vs. 3D-CRT.直肠癌新辅助放化疗中的剂量递增:容积调强弧形放疗同步整合加量与三维适形放疗的短期疗效及毒性比较
Medicina (Kaunas). 2025 Mar 11;61(3):483. doi: 10.3390/medicina61030483.
3
Two Decades of Progress in Personalized Medicine of Colorectal Cancer in Serbia-Insights from the Institute for Oncology and Radiology of Serbia.

本文引用的文献

1
Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.探索局部晚期直肠癌新辅助放化疗反应的新型遗传和血液学预测指标。
Front Genet. 2023 Aug 31;14:1245594. doi: 10.3389/fgene.2023.1245594. eCollection 2023.
2
Role of LGMN in tumor development and its progression and connection with the tumor microenvironment.亮氨酰基氨基肽酶在肿瘤发生、发展及其与肿瘤微环境的联系中的作用。
Front Mol Biosci. 2023 Feb 7;10:1121964. doi: 10.3389/fmolb.2023.1121964. eCollection 2023.
3
The ProteomeXchange consortium at 10 years: 2023 update.
塞尔维亚结直肠癌个性化医疗二十年进展——来自塞尔维亚肿瘤与放射学研究所的见解
Biomedicines. 2024 Oct 8;12(10):2278. doi: 10.3390/biomedicines12102278.
4
Characterization and proteomic analysis of plasma-derived small extracellular vesicles in locally advanced rectal cancer patients.局部进展期直肠癌患者血浆来源的小细胞外囊泡的表征和蛋白质组学分析。
Cell Oncol (Dordr). 2024 Oct;47(5):1995-2009. doi: 10.1007/s13402-024-00983-1. Epub 2024 Aug 20.
5
Methylenetetrahydrofolate reductase polymorphic variants C677T and A1298C in rectal cancer in Slavic population: significance for cancer risk and response to chemoradiotherapy.斯拉夫人群直肠癌中甲基四氢叶酸还原酶多态性变体C677T和A1298C:对癌症风险及放化疗反应的意义
Front Genet. 2024 Jan 15;14:1299599. doi: 10.3389/fgene.2023.1299599. eCollection 2023.
6
Performance and Dimensionality of Pretreatment MRI Radiomics in Rectal Carcinoma Chemoradiotherapy Prediction.直肠癌放化疗预测中预处理MRI影像组学的性能与维度
J Clin Med. 2024 Jan 12;13(2):421. doi: 10.3390/jcm13020421.
7
Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer.局部晚期直肠癌的全新辅助治疗的采用。
Curr Oncol. 2024 Jan 10;31(1):366-382. doi: 10.3390/curroncol31010024.
8
Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.探索局部晚期直肠癌新辅助放化疗反应的新型遗传和血液学预测指标。
Front Genet. 2023 Aug 31;14:1245594. doi: 10.3389/fgene.2023.1245594. eCollection 2023.
蛋白质组交换联盟成立十周年:2023 年更新。
Nucleic Acids Res. 2023 Jan 6;51(D1):D1539-D1548. doi: 10.1093/nar/gkac1040.
4
Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non-responders' tumor tissue.新辅助放化疗前后局部进展期直肠癌的蛋白质组学初步研究表明,无应答者肿瘤组织代谢活性较高。
Proteomics Clin Appl. 2023 Jan;17(1):e2100116. doi: 10.1002/prca.202100116. Epub 2022 Sep 7.
5
An Immune-Related Gene Signature for Predicting Neoadjuvant Chemoradiotherapy Efficacy in Rectal Carcinoma.一种用于预测直肠癌新辅助放化疗疗效的免疫相关基因标志物。
Front Immunol. 2022 May 6;13:784479. doi: 10.3389/fimmu.2022.784479. eCollection 2022.
6
DIA-MS proteome analysis of formalin-fixed paraffin-embedded glioblastoma tissues.DIA-MS 法对福尔马林固定石蜡包埋脑胶质瘤组织的蛋白质组学分析。
Anal Chim Acta. 2022 Apr 29;1204:339695. doi: 10.1016/j.aca.2022.339695. Epub 2022 Mar 12.
7
Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer.结直肠癌肿瘤微环境中发生上皮-间质转化的肿瘤细胞与自然杀伤细胞之间的相互作用
Front Cell Dev Biol. 2021 Nov 10;9:750022. doi: 10.3389/fcell.2021.750022. eCollection 2021.
8
The reactome pathway knowledgebase 2022.反应体通路知识库2022版。
Nucleic Acids Res. 2022 Jan 7;50(D1):D687-D692. doi: 10.1093/nar/gkab1028.
9
The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences.PRIDE 数据库资源在 2022 年:一个基于质谱的蛋白质组学证据的中心。
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552. doi: 10.1093/nar/gkab1038.
10
Prognostic Factors for Post-Recurrence Survival in Stage II and III Colorectal Carcinoma Patients.Ⅱ期和Ⅲ期结直肠癌患者复发后生存的预后因素。
Medicina (Kaunas). 2021 Oct 15;57(10):1108. doi: 10.3390/medicina57101108.